VTN and cancer: Further analysis of ligand-receptor pairs revealed that VTN-(ITGAV + ITGB5), SEMA4D-PLXNB2, GAS6-TYRO3, and FN1-(ITGA3 + ITGB1) were more prevalent in high-risk cancer cells.